You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023358024
Dec 2023118015
Jan 202499010
Feb 20247806
Mar 202417409
Apr 2024222017
May 2024150010
Jun 2024301021
Jul 2024248015
Aug 202410607
Sep 2024164012
Oct 2024186013
Nov 2024176010
Dec 2024164012
Jan 2025215020
Feb 202526010
Mar 20250014
Apr 20250012
May 2025107
Jun 2025005
Total27860249